Latest Articles
- Rethinking recovery in heart failure: Beyond improvement in left ventricular ejection fraction
The authors discuss 3 unresolved questions about de-escalating and escalating guideline-directed medical therapy in patients with improved ejection fraction.
- Teprotumumab for thyroid eye disease: A reality check
Initial enthusiasm for teprotumumab as therapy for thyroid eye disease has been tempered by longitudinal data suggesting that it often does not alter the natural disease course.
- Managing obesity in older adults
The goals of treating obesity in older adults are to ease its complications and improve functional status and quality of life, with or without weight loss.
- Failure to thrive in hospitalized older adults: More than a ‘social admission’
Failure to thrive documented as an admitting diagnosis presents an opportunity to identify, articulate, and begin to ameliorate the true underlying causes of the patient’s health deficits.
- What is the optimal time for bone density screening in patients with premature ovarian insufficiency?
Dual-energy x-ray absorptiometry should be performed at diagnosis, with the timing of repeat scans predicated on the patient’s clinical risk factors for fracture.
Lipoprotein(a) in clinical practice: What clinicians need to knowElevated lipoprotein(a) by itself is not an indication for statin therapy, but its presence supports earlier or more aggressive preventive therapy.
- Thyroid eye disease: What’s the latest?
A better understanding of the pathophysiology of this autoimmune disorder has led to innovative insights into its treatment, but long-term management remains a challenge.
- Low-dose colchicine for management of coronary artery disease
Current guidelines endorse adding low-dose colchicine to standard medical therapy for coronary artery disease prevention, but data show clinicians remain hesitant to use it for this indication.
